Octave is a biotechnology company that utilizes an intelligence platform to provide objective, quantitative insights for the management of multiple sclerosis (MS). By addressing the inadequacies of current subjective measurement systems, Octave enhances clinical decision-making and care coordination for patients, physicians, and payers.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MJFounders
Product
Problem
Current methods for assessing and managing multiple sclerosis (MS) rely heavily on subjective, qualitative measurements, leading to a lack of clarity in disease progression and suboptimal outcomes for patients, physicians, and payers. The absence of objective, quantitative data hinders effective clinical decision-making, care coordination, and the development of precision tools for managing the disease.
Solution
Octave Bioscience offers the MS Precision Care Solution, an intelligence platform designed to provide objective, multi-dimensional insights for managing MS. The platform utilizes the Octave MSDA Test, a multi-analyte biomarker blood test specifically developed to measure MS disease activity. By integrating data-driven insights into clinical decision-making, Octave aims to transform care across various clinical scenarios, enabling a new paradigm of care that complements the art of medicine with scientific clarity. The MSDA test results empower patients and providers to make informed care decisions with confidence.
Target Audience
The primary target audience includes physicians and healthcare providers specializing in multiple sclerosis, as well as patients seeking more clarity and objective data regarding their disease activity and progression.
Features
- Multi-analyte biomarker blood test developed specifically to measure MS disease activity
- Detailed, personalized reporting that empowers patients and providers to make care decisions with confidence
- Identification of clinically relevant, data-driven insights on MS disease activity
- Longitudinal monitoring capabilities to track disease progression over time
- Integration of technology, AI, and machine learning to power the art of medicine for MS providers
- Generation of novel data and insights that address unmet needs in MS care through rigorous scientific discipline